(Total Views: 743)
Posted On: 05/27/2020 1:18:44 AM
Post# of 72440
The 5/26 PR signifies a major science milestone achievement continuing the advancement of Brilacidin and positioning it as potentially the premier COVID-19 (CV19) treatment. We knew that Brilacidin was proven safe and effective in FDA phase 2 trials across 3 instances with 3 separate delivery mechanisms. The question was whether it would successfully prevent the CV19 viral load. IMO there is a strong likelihood of the RBL human lung testing being successful and per the information below I believe we will see government grant funding followed by human CV19 trials fast-tracking Brilacidin to market. The successful human kidney cell testing highlights PRed today include:
1) Brilacidin showed a dose-dependent inhibitory response in a human kidney cell line expressing hACE2.
2) Data supports Brilacidin’s potential to prevent SARS-CoV-2 binding to the hACE2 receptor, the method by which the novel coronavirus gains entry in human cells
3) an 85 percent inhibition at 100ug/ml (the highest concentration).
The testing at the Public Health Research Institute (PHRI) is happening at a very fast pace since they became the 3rd MTA signed on 5/5/20 only 3 weeks ago. This testing is taking place in parallel with the RBL testing and as stated by Leo; “We now have preliminary in vitro data from two separate independent laboratories that, cumulatively, support Brilacidin’s ability to act directly on the novel coronavirus, as a virucidal agent, and prevent viral binding to host cells. Across the coming weeks, we anticipate sharing additional anti-SARS-CoV-2 data from both research institutions as we work towards initiating a clinical study of Brilacidin for the treatment of COVID-19.”
And from last weeks PR:
“reduced the viral titer (load) of SARS-CoV-2 by 75 percent after only 1 hour of preincubation prior to infection at a concentration of 10μM as compared to vehicle control.”
“These statistically significant lab results strongly support Brilacidin’s prophylactic treatment potential given the drug’s potent and rapid virucidal activity—a unique ability, different from any other known drug currently in development to treat COVID-19, to inactivate the novel coronavirus prior to host cell entry and subsequent viral replication. A majority of antiviral agents targeting SARS-CoV-2 attempt to inhibit viral replication rather than completely eliminating the virus (virustatic versus virucidal).”
From the 10-Q dated 5/14/20
COVID-19 — Recently, due to the global COVID-19 pandemic, the Company has been approached by a number of organizations regarding a desire to conduct research on Brilacidin against the novel coronavirus, following release of information on its potential as a treatment. Material Transfer Agreements have been signed with academic institutions and Brilacidin drug substance (Brilacidin tetrahydrochloride) was provided for experimental research on the antiviral properties of Brilacidin. Available research data has been released (see Recent Developments), with subsequent testing now ongoing. Grant applications for funding of further development of Brilacidin in treatment of COVID-19 are either filed or in progress of being filed. Partnering opportunities, with industry and academic partners, are also ongoing. Given the safety and efficacy data already known about Brilacidin from multiple routes of administration, a Phase 2 study with Brilacidin (as intravenous solution) is in planning.
1) Brilacidin showed a dose-dependent inhibitory response in a human kidney cell line expressing hACE2.
2) Data supports Brilacidin’s potential to prevent SARS-CoV-2 binding to the hACE2 receptor, the method by which the novel coronavirus gains entry in human cells
3) an 85 percent inhibition at 100ug/ml (the highest concentration).
The testing at the Public Health Research Institute (PHRI) is happening at a very fast pace since they became the 3rd MTA signed on 5/5/20 only 3 weeks ago. This testing is taking place in parallel with the RBL testing and as stated by Leo; “We now have preliminary in vitro data from two separate independent laboratories that, cumulatively, support Brilacidin’s ability to act directly on the novel coronavirus, as a virucidal agent, and prevent viral binding to host cells. Across the coming weeks, we anticipate sharing additional anti-SARS-CoV-2 data from both research institutions as we work towards initiating a clinical study of Brilacidin for the treatment of COVID-19.”
And from last weeks PR:
“reduced the viral titer (load) of SARS-CoV-2 by 75 percent after only 1 hour of preincubation prior to infection at a concentration of 10μM as compared to vehicle control.”
“These statistically significant lab results strongly support Brilacidin’s prophylactic treatment potential given the drug’s potent and rapid virucidal activity—a unique ability, different from any other known drug currently in development to treat COVID-19, to inactivate the novel coronavirus prior to host cell entry and subsequent viral replication. A majority of antiviral agents targeting SARS-CoV-2 attempt to inhibit viral replication rather than completely eliminating the virus (virustatic versus virucidal).”
From the 10-Q dated 5/14/20
COVID-19 — Recently, due to the global COVID-19 pandemic, the Company has been approached by a number of organizations regarding a desire to conduct research on Brilacidin against the novel coronavirus, following release of information on its potential as a treatment. Material Transfer Agreements have been signed with academic institutions and Brilacidin drug substance (Brilacidin tetrahydrochloride) was provided for experimental research on the antiviral properties of Brilacidin. Available research data has been released (see Recent Developments), with subsequent testing now ongoing. Grant applications for funding of further development of Brilacidin in treatment of COVID-19 are either filed or in progress of being filed. Partnering opportunities, with industry and academic partners, are also ongoing. Given the safety and efficacy data already known about Brilacidin from multiple routes of administration, a Phase 2 study with Brilacidin (as intravenous solution) is in planning.
(21)
(1)Scroll down for more posts ▼
